A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

2009 ◽  
Vol 45 (5) ◽  
pp. 782-788 ◽  
Author(s):  
Glenwood Goss ◽  
Frances A. Shepherd ◽  
Scott Laurie ◽  
Isabelle Gauthier ◽  
N. Leighl ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document